Company: CERO
Filing Date: 2025-07-02
Form Type: 424B3
Source: 0001213900-25-061023
Chunk: 3

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-07-02
Form: 424B3
Chunk 3
---
 more closings, up to 10,000 shares of the Company’s Series D Preferred Stock, which are convertible
into shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), in a private placement
offering. As previously reported on the Current Report on Form 8-K filed with the SEC on June 6, 2025, the Company completed an Additional
Closing (as defined in the Securities Purchase Agreement) on June 5, 2025, pursuant to which the Company sold an additional 938 shares
of Series D Preferred Stock for gross proceeds of approximately $750,400.

On June 25, 2025, pursuant to the Securities Purchase
Agreement, the Company and certain Investors, mutually agreed to effect, and effected, an Additional Closing, with respect to 2,315 additional
shares of Series D Preferred Stock for gross proceeds of approximately $1,852,000. The rights, preferences and privileges of the Series
D Preferred Stock are set forth in the certificate of designations of rights and preferences of the Series D Preferred Stock (the “Certificate
of Designations”), filed with the Secretary of State of the State of Delaware on April 22, 2025. The offering and sale of the shares
of Series D Preferred Stock were issued and, upon conversion of the Series D Preferred Stock, the shares of Common Stock underlying the
Series D Preferred Stock will be issued, in each case, without registration under the Securities Act, in reliance on the exemptions provided
by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) as a transaction not involving a public
offering and Rule 506 promulgated under the Securities Act as sales to accredited investors, and in reliance on similar exemptions under
applicable state laws.

The description of the terms and conditions of
the Securities Purchase Agreement and the Certificate of Designations do not purport to be complete and each is qualified in its entirety
by the full text of Securities Purchase Agreement and the Certificate of Designations, as applicable, which are filed as exhibits to the
Company’s Current Reports on Form 8-K filed on April 22, 2025 and on April 25, 2025, respectively.

<div align='center'>1</div>

Item 9.01 Financial Statements and Exhibits.

(d)

| Exhibit Number |     | Description                                                                                                                                                                                                                                                                      |
| 3.1†